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COST-EFFECTIVENESS OF ACARBOSE IN ADDITION TO
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OBJECTIVES: Based on ﬁndings of a recent meta-analysis, eval-
uate long-term cost-effectiveness of acarbose given in addition to
existing treatments in type-2 diabetes patients in a German
setting. METHODS: The CORE Diabetes Model (peer-reviewed,
published, validated computer simulation model) was used to
project long-term clinical and cost outcomes in type-2 diabetes
patients receiving acarbose or placebo in addition to their exist-
ing treatment. Transition probabilities and risk adjustments
came from published sources. Treatment effects and baseline
cohort characteristics were based on recently published retro-
spective meta-analysis of placebo-controlled, double-blind, long-
term studies in type-2 diabetes, showing that acarbose treatment
was associated with improvements in HbA1c, systolic blood
pressure, lipid levels and BMI, and signiﬁcant reduction in the
risk of cardiovascular events. Direct costs were retrieved from
published sources and projected over patient lifetimes from a
third party health care payer perspective in Germany. Costs and
clinical beneﬁts were discounted at ﬁve percent per annum. Sen-
sitivity analyses were performed. RESULTS: Acarbose treatment
was associated with improvements in mean discounted life
expectancy of 0.21 years (7.78 ± 0.13 versus 7.57 ± 0.13 years
[mean ± standard deviation]) and quality-adjusted life
expectancy of 0.19 QALYs (5.36 ± 0.09 versus 5.17 ± 0.09
QALYs). Lifetime direct costs were on average €134 per patient
more expensive with acarbose than with placebo (€32,778 ±
1194 versus €32,643 ± 1285). Reduced complication costs par-
tially offset greater treatment costs in the acarbose arm, leading
to incremental cost-effectiveness ratios of €633 per life year
gained and €692 per quality-adjusted life year gained. Sensitiv-
ity analysis showed that these results were robust under varia-
tion in a range of assumptions. CONCLUSIONS: Addition of
acarbose to existing treatment was projected to lead to improve-
ments in life expectancy and quality-adjusted life expectancy, and
provide excellent value for money over patient lifetimes by
current standards in the German setting.
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OBJECTIVES: A recent European-based clinical trial showed
that basal/bolus treatment of 747 subjects with type-1 diabetes
with insulin detemir + human soluble insulin (IDet/HSI) signiﬁ-
cantly improved HbA1c (0.11%-points lower after 26 weeks)
and body weight (-0.61kg) compared to a regimen of neutral
protamine hagedorm insulin + human soluble insulin
(NPH/HSI). No signiﬁcant changes in hypoglycemic event rates
were observed. The aim of this analysis was to estimate the long-
term clinical and cost outcomes associated with IDet/HSI and
NPH/HSI regimens based on German cost data. METHODS: A
validated, peer-reviewed computer simulation model was used to
project the incidence of complications, life expectancy, quality-
adjusted life expectancy and costs over patient lifetimes. The
model simulated the progression of diabetes and its complica-
tions (cardiovascular disease, neuropathy, renal and eye disease).
Transition probabilities and risk adjustments were derived from
published clinical and epidemiological studies. Baseline cohort
characteristics and treatment effects were taken from the 26-
week clinical study. Direct costs of diabetes complications and
treatments were retrieved from published sources and accounted
from a German Health care payer perspective. An annual dis-
count rate of 3.5% was applied to costs and clinical beneﬁts.
RESULTS: Long-term basal/bolus therapy with IDet/HSI was
projected to decrease the incidence of diabetes-related complica-
tions, improve life expectancy (0.13 life years gained) and
quality-adjusted life expectancy (0.09 QALYs gained) compared
to NPH/HSI. Lower complication costs in the IDet/HSI arm par-
tially offset the increased costs of treatment. Mean total lifetime
costs were €1798 per patient higher with IDet/HSI than with
NPH/HSI, leading to incremental cost-effectiveness ratios of
€13,831 per life year gained and €19,978 per QALY gained.
CONCLUSIONS: Based on short-term clinical trial ﬁndings,
IDet/HSI was projected to reduce the incidence of long-term
complications, improve life expectancy and quality-adjusted life
expectancy, and can be considered to represent good value for
money by German and international standards.
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OBJECTIVES: Managing diabetes within accepted limits (A1c
°Ü 7%) is often complicated by the occurrence of hypoglycemia.
To reduce the risk of hypoglycemia, patients and clinicians some-
times settle for sub-optimal glucose control. However, sub-
optimal glycemic control increases the risk of diabetes-related
complications, having important economic consequences to the
health care system. Basal insulin glargine, has a distinctive A1c
hypoglycemia relationship compared to NPH insulin, with
reduced chance of hypoglycemia at lower A1c values. The objec-
tive is to assess the value of insulin glargine, compared to NPH
insulin, in insulin treated people with Type-2 diabetes who failed
to achieve an A1c °Ü 7%. METHODS: A 36-year time horizon
state transition model simulating the natural history of diabetes
and projecting clinical and economic beneﬁts of insulin glargine
compared to NPH insulin, was used. The study used Canadian
costs and utilities from previous publications. UKPDS and
DCCT provided the base for complication risks. The Ministry of
Health perspective was taken. RESULTS: Considering the 36-
year (lifetime) direct drug and complications costs, NPH was
found to be less expensive than insulin glargine ($1559 in type-
1 diabetes and $2248 in type-2 diabetes). However, since the
treatment with insulin glargine substantially reduced risk of
long-term complications, it produces greater life years (LY) (0.08
LY gained and 0.25 LY gained in type-1 and type-2 diabetes,
respectively) and quality-adjusted life years (QALYs) (0.07
QALY gained and 0.23 QALY gained in type-1 and type-2 dia-
betes, respectively). When considering glargine over NPH, the
incremental cost per LY gained and cost per QALY gained were
$20,317 and $23,717 for type-1 diabetes, and $9131 and $9804
for type-2 diabetes. CONCLUSIONS: For type-2 patients,
insulin glargine therapy results in substantial clinical beneﬁts and
represents an economical alternative to NPH insulin with com-
petitive cost-effectiveness ratios.
